Yang Chunyu, Wang Suzeng, Gao Ge, Xu Peiwen, Qian Mengyuan, Yin Yuan, Yao Surui, Huang Zhaohui, Bian Zehua
Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, 200 Hui He Road, Wuxi, Jiangsu, 214062, China.
Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, 214122, China.
J Cancer Res Clin Oncol. 2024 Dec 26;151(1):23. doi: 10.1007/s00432-024-06062-0.
Gastric cancer (GC) is one of the most common cancers worldwide, with increasing incidence and mortality rates. It is typically diagnosed at advanced stages, leading to a poor prognosis. GC is a highly heterogeneous disease and its progression is associated with complex interplay between genetic and environmental factors. Identifying novel genes and pathways involved in GC development is crucial for improving the therapeutic outcome. Regulator of Telomerase Length 1 (RTEL1) has been found to maintain telomere stability through its helicase activity, facilitating telomere reconstruction and repair. However, the precise role of RTEL1 in human cancers, particularly in GC, is not yet fully understood. In this study, we observed significantly increased RTEL1 expression in GC tissues, which was associated with a poor prognosis. Functionally, RTEL1 promotes GC cell proliferation both in vitro and in vivo. Additionally, RTEL1 appears to regulate multiple signaling pathways, with a particular promoting effect on the cell cycle progression. Notably, CDC23 and TRIP13 are potential downstream target genes of RTEL1, which may mediate its tumor-promoting effects in GC. These findings suggest that RTEL1 plays a critical role in GC tumorigenesis and could be a promising target for the therapy and prognosis of GC.
胃癌（GC）是全球最常见的癌症之一，其发病率和死亡率呈上升趋势。它通常在晚期被诊断出来，导致预后不良。GC是一种高度异质性疾病，其进展与遗传和环境因素之间的复杂相互作用有关。识别参与GC发展的新基因和途径对于改善治疗效果至关重要。端粒酶长度调节因子1（RTEL1）已被发现通过其解旋酶活性维持端粒稳定性，促进端粒重建和修复。然而，RTEL1在人类癌症，特别是在GC中的精确作用尚未完全了解。在本研究中，我们观察到GC组织中RTEL1表达显著增加，这与预后不良有关。在功能上，RTEL1在体外和体内均促进GC细胞增殖。此外，RTEL1似乎调节多种信号通路，对细胞周期进程有特别的促进作用。值得注意的是，CDC23和TRIP13是RTEL1的潜在下游靶基因，它们可能介导其在GC中的促肿瘤作用。这些发现表明，RTEL1在GC肿瘤发生中起关键作用，可能是GC治疗和预后的一个有希望的靶点。
